Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Haloperidol

FDA-approved product (tablet, oral), marketed as Haldol, Haldol Solutab, Haloperidol and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Haloperidol
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conduct disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia
  • Tics
  • Tourette syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Butyrophenone derivatives
FDA pharmacologic class
Typical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis68.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Haloperidol in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Haloperidol with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Haloperidol For Outpatient Symptom Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome in the Emergrency Department

    NCT07726069 · start 2026-11

    Registered record
    Registry ID
    NCT07726069
    Conditions
    Cannabinoid Hyperemesis Syndrome
    Interventions
    Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2028-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabinoid Hyperemesis Syndrome
    InterventionHaloperidol
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Comparison of Haloperidol and Ondansetron in Reducing Postoperative Nausea and Vomiting in RA-SAB Patients

    NCT07087925 · start 2025-01-15

    Registered record
    Registry ID
    NCT07087925
    Conditions
    Postoperative Nausea and Vomiting (PONV); Subarachnoid Block; Spinal Anesthesia
    Interventions
    Haloperidol; Ondansetron 4mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-01-15
    Completion
    2025-05-15
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting (PONV); Subarachnoid Block; Spinal Anesthesia
    InterventionHaloperidol; Ondansetron 4mg
    PhaseNot applicable
    Registry statusCompleted

  • The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM

    NCT06218524 · start 2024-12-01

    Registered record
    Registry ID
    NCT06218524
    Conditions
    Glioblastoma Multiforme
    Interventions
    Haloperidol Tablets; Temozolomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-12-01
    Completion
    2028-07-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioblastoma Multiforme
    InterventionHaloperidol Tablets; Temozolomide
    PhasePhase 2
    Registry statusNot yet recruiting

  • Comparative Efficacy of Dexamethasone - Ondansetron Versus Dexamethasone - Haloperidol in Reducing PONV

    NCT06428084 · start 2023-11-01

    Registered record
    Registry ID
    NCT06428084
    Conditions
    Laparoscopic Cholecystectomy
    Interventions
    Ondansetron; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2024-02-28
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLaparoscopic Cholecystectomy
    InterventionOndansetron; Haloperidol
    PhasePhase 2
    Registry statusCompleted

  • Maternal And Infant Antipsychotic Study

    NCT06049953 · start 2023-09-29

    Registered record
    Registry ID
    NCT06049953
    Conditions
    Antipsychotics; Pregnancy
    Interventions
    Antipsychotics; Non-antipsychotic medication; No Medication
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2023-09-29
    Completion
    2028-01-01
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntipsychotics; Pregnancy
    InterventionAntipsychotics; Non-antipsychotic medication; No Medication
    PhaseNot recorded
    Registry statusRecruiting

  • Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

    NCT05065567 · start 2021-08-30

    Registered record
    Registry ID
    NCT05065567
    Conditions
    Cyclic Vomiting Syndrome
    Interventions
    Droperidol; Haloperidol; Ondansetron 8mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2021-08-30
    Completion
    2023-11-20
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCyclic Vomiting Syndrome
    InterventionDroperidol; Haloperidol; Ondansetron 8mg
    PhasePhase 3
    Registry statusTerminated

  • Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery

    NCT05932394 · start 2021-07-01

    Registered record
    Registry ID
    NCT05932394
    Conditions
    Delirium; Postoperative Delirium; Cardiac Surgery
    Interventions
    Projection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery; the usual unit treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2021-07-01
    Completion
    2023-06-26
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Postoperative Delirium; Cardiac Surgery
    InterventionProjection of Visual Material on Postoperative Delirium in Patients Undergoing Cardiac Surgery; the usual unit treatment
    PhaseNot applicable
    Registry statusCompleted

  • Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis

    NCT04529226 · start 2020-11-26

    Registered record
    Registry ID
    NCT04529226
    Conditions
    Psychosis; Intellectual Disability
    Interventions
    Clozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-11-26
    Completion
    2025-12-30
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsychosis; Intellectual Disability
    InterventionClozapine; haloperidol, pimozide, olanzapine, risperidone, amisulpride
    PhasePhase 2
    Registry statusUnknown

  • Treatment Strategies in CHS

    NCT04176055 · start 2020-10-13

    Registered record
    Registry ID
    NCT04176055
    Conditions
    Cannabis Hyperemesis Syndrome
    Interventions
    Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2020-10-13
    Completion
    2022-06-01
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCannabis Hyperemesis Syndrome
    InterventionHaloperidol
    PhasePhase 4
    Registry statusCompleted

  • Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery

    NCT04081545 · start 2019-12-24

    Registered record
    Registry ID
    NCT04081545
    Conditions
    Opioid Use, Unspecified; Bariatric Surgery Candidate; Anesthesia
    Interventions
    Opioid Anesthetics; Non Opioid Analgesics
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-12-24
    Completion
    2023-06-30
    Enrolment
    181

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use, Unspecified; Bariatric Surgery Candidate; Anesthesia
    InterventionOpioid Anesthetics; Non Opioid Analgesics
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions

    NCT04411940 · start 2019-11-15

    Registered record
    Registry ID
    NCT04411940
    Conditions
    Bioequivalence
    Interventions
    Haloperidol Tablets, Mylan Pharmaceuticals Inc.; Haloperidol Tablets, Cycle Pharmaceuticals Ltd
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-11-15
    Completion
    2019-12-18
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionHaloperidol Tablets, Mylan Pharmaceuticals Inc.; Haloperidol Tablets, Cycle Pharmaceuticals Ltd
    PhasePhase 1
    Registry statusCompleted

  • Rapid Agitation Control With Ketamine in the Emergency Department

    NCT03375671 · start 2018-05-29

    Registered record
    Registry ID
    NCT03375671
    Conditions
    Violent Aggressive Behavior; Ketamine
    Interventions
    Ketalar; Midazolam injection; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-05-29
    Completion
    2020-03-12
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionViolent Aggressive Behavior; Ketamine
    InterventionKetalar; Midazolam injection; Haloperidol
    PhasePhase 2
    Registry statusCompleted

  • Haloperidol for Delirium in Adult Critically Ill Patients

    NCT03628391 · start 2018-02-22

    Registered record
    Registry ID
    NCT03628391
    Conditions
    Delirium; Critical Illness; Intensive Care Psychosis; Cognitive Impairment; Cognitive Decline
    Interventions
    Haloperidol; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2018-02-22
    Completion
    2021-01-23
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Critical Illness; Intensive Care Psychosis; Cognitive Impairment +1 more
    InterventionHaloperidol; Placebo
    PhasePhase 3
    Registry statusTerminated

  • Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)

    NCT03317067 · start 2017-12-21

    Registered record
    Registry ID
    NCT03317067
    Conditions
    Delirium; Agitation
    Interventions
    Dexmedetomidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-12-21
    Completion
    2023-02-23
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Agitation
    InterventionDexmedetomidine; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Sleep/Wake Protocol Implementation to Improve Sleep Quality in the ICU

    NCT03313115 · start 2017-10-11

    Registered record
    Registry ID
    NCT03313115
    Conditions
    Sleep Deprivation; Delirium
    Interventions
    Sleep/Wake Protocol
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-10-11
    Completion
    2018-03-14
    Enrolment
    685

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Deprivation; Delirium
    InterventionSleep/Wake Protocol
    PhaseNot recorded
    Registry statusCompleted